A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

Conditions

• Hypertension, Pulmonary

Interventions

• DRUG: Sotatercept 0.3 mg/kg
• DRUG: Placebo
• DRUG: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA